SEOUL, Jan. 6 (Korea Bizwire) — South Korean biotech company GC Pharma said Wednesday it has completed phase two clinical trials of its plasma therapy treatment for the novel coronavirus. The plasma therapy, known as GC5131A, is a type of hyperimmune globulin drug that uses blood plasma taken from people who have fully recovered from [...]
SEOUL, Nov. 3 (Korea Bizwire) — South Korean biotech company GC Pharma has begun additional production of its plasma therapy treatment for the novel coronavirus amid growing demand for treatment purposes, company officials said Tuesday. The plasma therapy, known as GC5131, is a type of hyperimmune globulin drug that uses blood plasma taken from people [...]
SEOUL, Sept. 21 (Korea Bizwire) — South Korea’s biotech company GC Pharma will soon begin advanced clinical trials of its plasma therapy treatment for the novel coronavirus both locally and globally, company officials said Monday. The plasma therapy, known as GC5131, is a type of hyperimmune globulin drug that uses blood plasma taken from people [...]
SEOUL, April 16 (Korea Bizwire) — South Korean health authorities on Thursday unveiled blood collection guidelines for plasma therapy of the novel coronavirus patients. The Korea Centers for Disease Control and Prevention (KCDC) advised doctors to collect blood plasma from COVID-19 survivors, 14 days after they were declared virus-free and released from quarantine. The therapy [...]
SEOUL, April 7 (Korea Bizwire) — South Korea will set guidelines for the treatment of coronavirus patients with plasma from those who have recovered from COVID-19, a senior health official said Tuesday, after two patients here were declared cured upon receiving the therapy. The therapy involves infusions of blood plasma from coronavirus survivors to virus [...]